In this video-based program, a multispecialty expert panel provides perspectives on the diagnosis and treatment of metabolic dysfunction–associated steatotic liver disease (MASLD) and its progressive subtype, metabolic dysfunction–associated steatohepatitis (MASH), which pose a critical and escalating public health crisis, particularly...

The management of cystic fibrosis (CF) has been radically transformed with the introduction of effective modulators of the protein underlying the pathogenesis of the disease. In addition, newborn screening has improved outcomes through early detection and intervention on gastrointestinal and...

This Burst CME features an expert-led video discussion on TL1A pathophysiology, which has led to a promising new class of biologics for moderate-to-severe IBD with potential to transform care by addressing both inflammatory and fibrostenotic complications. Emerging evidence on TL1A...

Research revealing that overexpression of TL1A drives key pathological pathways in inflammatory bowel disease (IBD) has accelerated the development of biologic therapies aimed at inhibiting this ligand. Early studies of investigational anti-TL1A agents—including tulisokibart, afimkibart, and duvakitug—demonstrate encouraging outcomes in...

Chronic idiopathic constipation (CIC), also known as functional constipation, has a significant impact on patients and the health care system. However, it may not be diagnosed in a timely manner due to patient embarrassment and low clinician awareness of appropriate...